In the March 2006 issue of Annals of Oncology, Dr. Auperin et al. [1] conducted a meta-analysis addressing the role of concomitant platinum-based radio-chemotherapy in locally advanced non-small-cell lung cancer (NSCLC) patients. In this meta-analysis, the authors included both cisplatin-and carboplatin-based regimens within platinum-based chemotherapy. They demonstrated that the concomitant platinum-based radio-chemotherapy yielded a significant absolute benefit of chemotherapy of 4% at 2 years compared with the radiotherapy alone. In spite of indirect comparisons, there was no significant difference between cisplatin-and carboplatin-based chemotherapy in terms of overall survival.
